AI in Cardiovascular Markets 2027–2031

AI in Cardiovascular Markets: Market Forecast, Competitive Landscape, Regulation and World Metropolitan Area Market Sizes, 2027–2031

Global forecasts by condition, data modality, clinical use, end user and product, for 14 countries and regions and 237 metropolitan areas, with 40 company profiles. Artificial intelligence that reads the ECG, echo, cardiac CT and MRI, wearables, heart sounds and clinical data: AI analysis services, software and SaaS, AI-enabled devices and wearables, and data and platform services.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Cardiology is where AI in diagnostics proves it can get paid. AI plaque analysis and FFR-CT now earn their own Medicare payment, AI-read ECG patches have replaced the Holter, and ECG-AI finds weak hearts, amyloidosis and pulmonary hypertension in a standard 12-lead tracing. The market grows from $2,240.0 million in 2026 to $8,600.0 million in 2031, at 30.9% a year, as the algorithm, not the scan, becomes what the payer pays for.

Market Size 2026: USD $2,240M Market Size 2031: USD $8,600M CAGR: 30.9%

Situation Analysis: what is really happening

• CT catches up with the ECG. Cardiac CT & MRI is the fastest-growing data modality at 35.1% a year, rising from 20.5% to 24.0% of the market, as AI plaque analysis and FFR-CT spread.
• The AI service gets paid. AI Analysis Services grow 33.9% a year, from 24.5% to 27.5% of the market, after CMS set payment for the new AI plaque analysis code and Aetna began covering it.
• Heart failure moves up. Heart Failure & Cardiomyopathy grows 34.1% a year as ECG-AI and echo AI find low ejection fraction, amyloidosis and pulmonary hypertension earlier.
• Primary care joins in. Primary Care & Retail Clinics is the fastest-growing end user at 36.5% a year, as AI stethoscopes, ECG-AI and guided ultrasound let non-specialists find heart disease.
• Consolidation and conflict. Medtronic completed its $585 million acquisition of CathWorks, iRhythm bought VitalConnect, and HeartFlow sued Cleerly and Elucid over patents.
• China is the growth engine. China grows 39.8% a year, the fastest of any country, while the USA remains more than half of the market.

Company Analysis: who is positioned, who is exposed

• HeartFlow, Cleerly, Elucid, Caristo, Artrya, Keya Medical, Shukun and Circle Cardiovascular Imaging: Cardiac CT and imaging AI, from per-case services to software.
• iRhythm, AliveCor, Anumana, Tempus AI, Idoven, Powerful Medical, Eko Health and Biotricity: ECG, ambulatory monitoring and heart-sound AI.
• Ultromics, Us2.ai, Viz.ai, Echo IQ, UltraSight, Cardiosense, Implicity and iCardio.ai: Echocardiography, heart failure and remote-monitoring AI.
• GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Medtronic, Boston Scientific, Abbott and Apple: Imaging, device and consumer majors building AI into scanners, monitors, implants and watches.
• Roche, Rainmed, United Imaging Intelligence, VUNO, Medical AI, Fujifilm, Samsung and Withings: Cardiac biomarker algorithms and Asian imaging, ECG and wearable AI.

In all, 40 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How large is the market for AI in cardiovascular care, and how fast will it grow?
• Which conditions, data modalities and clinical uses grow fastest?
• How do per-case AI services, software, AI in devices and wearables, and data services compare?
• What do Medicare codes 75577 and 75580, the Category III AI codes and FDA and EU rules mean for cardiac AI?
• Who leads in FFR-CT, plaque analysis, ECG-AI, echo AI and remote monitoring?
• How large is each country market, and which metropolitan areas lead?

What's inside

• 368 pages, 23 chapters, 102 tables and 53 figures
• Forecasts for 2027–2031 from a 2026 base year, by condition, data modality, clinical use, end user and product, for 14 countries and regions
• Market sizes for 237 world metropolitan areas in 2026 and 2031, with the top 30 and fastest-growing metros
• Conditions, data modalities and clinical uses; end users and business models; foundation models and data; evidence, adoption and clinical workflow
• Regulation and reimbursement; 10 market-moving developments; SWOT, Porter's Five Forces and strategic recommendations
• 40 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Cardiac imaging, device and diagnostics companies: decide where AI adds diagnostic scope and value, and how to price it.
• Cardiovascular AI developers: size target segments and plan regulatory and reimbursement routes.
• Cardiology and hospital leaders: benchmark adoption, evidence and the business case for AI.
• Investors and strategic acquirers: assess consolidation, litigation and growth by segment and region.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional, co-author of "The Radioimmunoassay of Angiotensinogen by Antibody Trapping," and has worked in laboratory testing and management for over 20 years. He has written HSR's research on artificial intelligence in diagnostics since its first edition and presents HSR's Smart IVD webinars.